Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its ...

Abbott Laboratories (ISIN US0028241000) saw BTIG cut its price target from USD 134.00 to USD 125.00 on October 21, 2026, ...

The nutrition separation is anticipated to be completed by the end of 2027, structured as a tax-free distribution to ...

Shares of Abbott Laboratories ABT rallied 1.99% to $102.51 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

Wall Street's major averages finished in the red on Friday as technology stocks continued to lag amid artificial intelligence spending fears and a continued rise in oil prices due to geopolitical ...

Shares in Abbott Laboratories ($ABT) were down 4% in pre-market trading today as it announced that it planned to separate its global Nutrition business into an ...

Abbott, which also makes diagnostics and medical devices, will spin off the unit that makes Similac and Ensure into its own ...

Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult ...

Abbott's second-quarter 2026 earnings gave investors a good reason to be bullish. Sales rose 13% to about $12.6 billion, while adjusted earnings per share (EPS) rose to $1.31. The healthcare company ...